Post-marketing clinical trial of Pegasys [peginterferon alfa-2a] 180microg for subcutaneous injection in patients with chronic hepatitis C. General clinical study in interferon (IFN)-treated and IFN-untreated chronic hepatitis C patients, except for those infected with high viral load of genotype 1b.

Trial Profile

Post-marketing clinical trial of Pegasys [peginterferon alfa-2a] 180microg for subcutaneous injection in patients with chronic hepatitis C. General clinical study in interferon (IFN)-treated and IFN-untreated chronic hepatitis C patients, except for those infected with high viral load of genotype 1b.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 16 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Nov 2010 Planned end date changed from 1 Apr 2011 to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top